When exogenous myonectin supplementation is added, skeletal muscle atrophy is prevented by the AMPK α2/PGC-1α4/IGF-1-dependent pathway (63); however, in human trials, there were no limiting differences in serum myonectin levels among 142 older adults with or without sarcopenia (62). This evidence concerns the gene IGF1 and sarcopenia.